The Pharmacokinetics and Safety of Ritonavir-boosted Indinavir 600/100mg Bid Combined With NRTIs in ARV naïve HIV/TB Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy

NCT00411996 Phase 1/Phase 2 COMPLETED

We believe that there is a strong rationale for the study of IDV/r 600/100 bid as a boosted-PI combination that, in the presence of RMP, is able to produce a satisfactory PK profile associated with adequate antiretroviral potency, tolerability and efficacy.

Details

Lead sponsor	The HIV Netherlands Australia Thailand Research Collaboration
Phase	Phase 1/Phase 2
Status	COMPLETED
Enrolment	20
Start date	2006-12
Completion	2009-12

Conditions

• HIV Infections
• Tuberculosis

Interventions

• indinavir/ritonavir

Primary outcomes

• pharmacokinetics of ritonavir-boosted indinavir 600/100mg bid in combination with rifampicin-containing anti-TB therapy. — 2 weeks

Countries

Thailand